Roche has revealed the data behind a positive phase 3 trial for its oral BTK inhibitor fenebrutinib in primary progressive multiple sclerosis (PPMS), revealing that it was at least as effective as its ...

After being vacant for the past year, a group of 100-something-year-old buildings in downtown St. Pete has been transformed ...

Downtown St. Petersburg got a big pop of color over the weekend. Why it matters: The pink paint job on several vacant ...

Four buildings on the corner of 4th St. S and 4th Ave. S in downtown St. Petersburg got a bright pink makeover ahead of ...

Turk selected the collection’s three fabric designs, pairing them with her favorite Santa Barbara Umbrella colors, trims, and silhouettes to create the shading beauties available at the Trina Turk ...

Buckhead Village welcomes Roche Bobois, bringing high-end French furniture and home accessories to Atlanta’s luxury corridor.

Roche has shared the numbers behind its phase 3 win in primary progressive multiple sclerosis (PPMS), linking its BTK inhibitor to a 12% reduction in the risk of disability progression compared to ...

Roche obesity drug shows 22.5% weight loss in Phase-II trial Roche focuses on catching Lilly in $150 billion obesity market Investors lukewarm on CT-388 results in crowded market The company said on ...

Roche’s dual GLP-1/GIP receptor agonist has been tied to 22.5% weight loss at 48 weeks, validating the company’s decision to move the asset into phase 3 studies this quarter. The Swiss Big Pharma ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. Roche plans to launch Phase 3 studies of its leading obesity candidate ...

Roche’s dual agonist CT-388 achieves 22.5% weight loss in phase two trials, prompting acceleration and a bid to secure a strategic market position The Swiss pharmaceutical giant Roche has announced ...

Roche took control of CT-388 with a $2.7 billion acquisition of Carmot Therapeutics more than two years ago. That deal was one of many that large pharmaceutical companies have forged to rush into a ...